Biocompatibility of Intracanal Medications Based on Calcium Hydroxide

Abstract EN

Objective.

The aim of this study was to evaluate the rat subcutaneous tissue reaction to calcium hydroxide-based intracanal medicaments, UltraCal XS (calcium hydroxide, barium sulphate, aqueous matrix), Hydropast (calcium hydroxide, barium sulphate, and propyleneglycol), and Calen (Calcium hydroxide, zinc oxide, colophony, and polyethyleneglycol), used as a control.

Methods.

Forty-eight rats (Rattus Norvegicus Holtzman) were distributed in three groups: Calen, UltraCal XS, and Hydropast.

Polyethylene tubes filled with one of the medicaments were implanted in the dorsal subcutaneous.

After 7 and 30 days, the implants were removed and the specimens were fixed and embedded in paraffin.

Morphological and quantitative analyses were carried out in the HE-stained sections.

The numerical density of inflammatory cells in the capsule was evaluated and statistical analyses were performed (P≤0.05).

Results.

At 7 days, all materials induced an inflammatory reaction in the subcutaneous tissue adjacent to the implants.

In all groups, a significant reduction in the number of inflammatory cells and giant cells was verified in the period of 30 days.

Conclusion.

These results indicate that the calcium hydroxide-based medicaments evaluated present biocompatibility similar to Calen.